BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

8.015 -0.085 (-1.05%)

Delayed Quote Updated: 1:50 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗

August 04, 2025

CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year.

Via Stocktwits

Topics Artificial Intelligence Earnings

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth ↗

August 04, 2025

BioCryst Pharmaceuticals (BCRX) beats Q2 2025 estimates with strong revenue and profit growth, driven by ORLADEYO sales. Shares rise ~5% pre-market.

Via Chartmill

BioCryst (BCRX) Q2 Revenue Jumps 50% ↗

August 04, 2025

Via The Motley Fool

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

Earnings Outlook For BioCryst Pharma ↗

August 01, 2025

Via Benzinga

BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering ↗

June 27, 2025

BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position.

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish ↗

June 27, 2025

As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up...

Via Stocktwits

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

June 03, 2025

BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.

Via Chartmill

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

May 13, 2025

BIOCRYST PHARMACEUTICALS (BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Via Chartmill

BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish ↗

May 05, 2025

BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year.

Via Stocktwits

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors ↗

May 05, 2025

BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.

Via Benzinga

Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗

May 05, 2025

Via Benzinga

These stocks are gapping in today's session ↗

May 05, 2025

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

May 05, 2025

Via Benzinga

BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased ↗

May 05, 2025

BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 05, 2025

Via Benzinga

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today ↗

February 24, 2025

Via The Motley Fool

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript ↗

February 24, 2025

BCRX earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings ↗

February 24, 2025

BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.

Via Benzinga

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

BCRX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For February 24, 2025 ↗

February 24, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 04, 2024

Via Benzinga

Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

August 06, 2024

EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END

Via FinancialNewsMedia

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript ↗

August 05, 2024

BCRX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

August 06, 2024

From FN Media Group LLC

Via GlobeNewswire

7 Small-Cap Stocks to Buy for Large-Scale Gains ↗

July 30, 2024

Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.

Via InvestorPlace

3 Insider-Buy Stocks to Add to Your Watchlist Now

July 09, 2024

Insiders are buying these stocks that should be on your radar, but only two are set up to rebound and move higher today; the third may move lower first.

Via MarketBeat

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 15, 2024

Via Benzinga

NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday ↗

May 15, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.